Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

The
proposed combination will create a differentiated global biosimilars platform
that leverages Kashiv BioSciences’ development and manufacturing capabilities
with Amneal Pharmaceuticals’ commercial strengths

Complementary
acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial
position for affordable medicines

PISCATAWAY,
New Jersey, April 22, 2026: Kashiv BioSciences, LLC (“Kashiv”), today
announced that it has entered into a definitive agreement to be acquired by
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is
subject to approval by Amneal shareholders, receipt of regulatory approvals and
satisfaction of customary closing conditions and is expected to close in the
second half of 2026.

This
acquisition combines Kashiv’s extensive expertise in the development and
manufacturing of biosimilars with Amneal’s scale and commercialization
capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations
in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and
is a leading biopharmaceutical company with one of the largest affordable
medicine businesses in the U.S.

Together,
the companies will establish a fully integrated biosimilar platform at scale,
to deliver high-quality, affordable therapies, expand patient access, and
strengthen their position in the global biopharmaceutical landscape.

“We
are thrilled to combine Kashiv’s highly complementary portfolio and
capabilities with Amneal at this critical inflection point for the biosimilar
market, particularly in the U.S.,” said Dr. Sandeep Athalye, Chief
Executive Officer at Kashiv. “Our companies share a deep-rooted commitment
to high-quality, complex medicines, and this transaction builds on the
meaningful work we have accomplished through our partnership of more than ten
years. We look forward to building on our proven track record of product
approvals and advancing our biosimilars pipeline as we work together to expand
patient access to life-changing therapies.”

“As
biosimilar adoption accelerates and the industry enters an unprecedented period
of biologic loss of exclusivity, we see a compelling opportunity to establish
leadership and scale in a rapidly expanding market,” said Chirag Patel,
Co-Founder and Co-Chief Executive Officer of Amneal. “With Kashiv, Amneal
becomes a fully integrated global biosimilars leader at the forefront of the
next wave of U.S. affordable medicines. This acquisition is a natural next step
in our strategy to build a leading, diversified biopharmaceutical company, and
we are confident it will drive accelerated growth and long-term value
creation.”

“This
acquisition establishes Amneal as a fully integrated global biosimilar platform
at scale,” said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal.
“By combining Kashiv’s deep R&D and manufacturing capabilities with our
commercial strength, we are creating a differentiated platform well-positioned
to deliver a strong and consistent cadence of biosimilar launches going
forward. Together, we will expand access to high-quality, affordable biologic
medicines for patients while driving long-term growth.”

J.P.
Morgan is serving as Kashiv’s financial advisor for the transaction, Holland
& Knight LLP is serving as legal counsel, and Dhinal Shah Associates is
serving as India legal counsel.

About
Kashiv BioSciences

Kashiv
BioSciences, LLC is a vertically integrated biopharmaceutical company with
numerous commercial and advanced clinical-stage assets and is among the few
U.S.-based companies to both manufacture and receive marketing authorization
for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with
its subsidiaries in India (collectively, “Kashiv BioSciences”) operates with
robust infrastructure and highly skilled teams that provide global R&D,
clinical, manufacturing, regulatory, and IP capabilities. We believe our
people, partners, and shared purpose fuel our work to advance patient care and
access to important medicines. For additional information, please visit kashivbiosciences.com and
follow us on LinkedIn.

About
Amneal

Amneal
Pharmaceuticals, Inc. (NASDAQ: AMRX), headquartered in Bridgewater, New Jersey,
is a diversified, global biopharmaceutical leader focused on expanding access
to affordable and innovative medicines. Amneal was founded in 2002 by brothers
and co-CEOs Chirag and Chintu Patel and built on the belief that innovation
only matters if it’s accessible. Today, Amneal has a diverse and growing
portfolio of approximately 300 complex generic, specialty and biosimilar
medicines, delivering more than 160 million prescriptions annually, primarily
in the United States. Our Affordable Medicines segment spans retail generics,
injectables, and biosimilars. Our Specialty segment provides branded treatments
in neurology, including Parkinson’s disease and migraine, and endocrinology.
Our AvKARE segment distributes pharmaceuticals and medical products to U.S.
federal, retail, and institutional customers. For additional information,
please visit amneal.com and follow us on LinkedIn.